



Team,

It is an exciting time for the Texas Biomedical Device Center. Just six years ago we embarked on this incredible journey to improve the lives of those suffering from neurological injuries. In that short time our team has published over 100 peer-reviewed papers, trained hundreds of students to conduct rigorous research, raised over \$37 million in external funding, and treated 150 people using Targeted Plasticity Therapy in 5 clinical trials. Together we have developed one of the most rigorous and prolific research centers in the world. The quality of your research is second to none.

Your success is propelling us into the next exciting phase of the center's life. We just completed the development of our own class 3 implantable device to deliver targeted plasticity therapy. We have also developed tools to allow us to deliver Targeted Plasticity for a wide range of neurological conditions in the clinic and at home. In the next few weeks, we will submit investigational device exemptions to the FDA to conduct our first two safety studies on our implantable system. We expect to be running clinical trials in patients with PTSD or spinal cord injury as early as May of 2019.

**Our goal is to become the world's leader in treating neurological injuries.**

If we are to reach this profound goal, we must translate our technologies into commercially viable solutions. The rigors of manufacturing a class 3 implantable system cannot be sustained at a university. As a result, Dr. Rennaker and I have put together a strategic plan that cultivates partnerships with multiple companies to commercialize the technology that has been developed by TxBDC. Dr. Rennaker has graciously agreed to take the next 12 to 24 months to work with our corporate partners to shepherd these technologies through the rigorous hurdles ahead.

This commitment to our outside partners required Dr. Rennaker to request a reduced appointment at UTD and as a result he requested that I take over as Executive Director. The Provost approved this change in leadership.

Please join me in thanking Dr. Rennaker for his leadership and dedication to serving those in need and more specifically focusing on helping our wounded warriors. While titles may change, the leadership and vision for the center has not changed. Dr. Rennaker and I continue to work together with the greatest research lab in the world. We are honored to lead such a wonderful team.

Sincerely,

Dr. Michael Kilgard  
Interim Director of the Texas Biomedical Device Center



Dr. Robert Rennaker  
Chief Technology Officer  
and Associate Director



Dr. Michael Kilgard  
Chief Science Officer  
and Interim Director